JP2023511282A5 - - Google Patents
Info
- Publication number
- JP2023511282A5 JP2023511282A5 JP2022542946A JP2022542946A JP2023511282A5 JP 2023511282 A5 JP2023511282 A5 JP 2023511282A5 JP 2022542946 A JP2022542946 A JP 2022542946A JP 2022542946 A JP2022542946 A JP 2022542946A JP 2023511282 A5 JP2023511282 A5 JP 2023511282A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- day
- recombinant bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960950P | 2020-01-14 | 2020-01-14 | |
| US62/960,950 | 2020-01-14 | ||
| US202062993301P | 2020-03-23 | 2020-03-23 | |
| US62/993,301 | 2020-03-23 | ||
| US202063028902P | 2020-05-22 | 2020-05-22 | |
| US63/028,902 | 2020-05-22 | ||
| US202063065752P | 2020-08-14 | 2020-08-14 | |
| US63/065,752 | 2020-08-14 | ||
| US202063089758P | 2020-10-09 | 2020-10-09 | |
| US63/089,758 | 2020-10-09 | ||
| US202063091620P | 2020-10-14 | 2020-10-14 | |
| US63/091,620 | 2020-10-14 | ||
| US202063111376P | 2020-11-09 | 2020-11-09 | |
| US63/111,376 | 2020-11-09 | ||
| PCT/US2021/013401 WO2021146397A1 (en) | 2020-01-14 | 2021-01-14 | Bacteria engineered to treat disorders in which oxalate is detrimental |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511282A JP2023511282A (ja) | 2023-03-17 |
| JP2023511282A5 true JP2023511282A5 (https=) | 2024-01-22 |
Family
ID=76864711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542946A Pending JP2023511282A (ja) | 2020-01-14 | 2021-01-14 | シュウ酸塩が有害となる障害を治療するための遺伝子改変細菌 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230092431A1 (https=) |
| EP (1) | EP4090343A4 (https=) |
| JP (1) | JP2023511282A (https=) |
| CN (1) | CN115335066A (https=) |
| AU (1) | AU2021207879A1 (https=) |
| BR (1) | BR112022013867A2 (https=) |
| CA (1) | CA3167754A1 (https=) |
| IL (1) | IL294710A (https=) |
| WO (1) | WO2021146397A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| WO2022204406A1 (en) * | 2021-03-24 | 2022-09-29 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| GB202402011D0 (en) | 2024-02-14 | 2024-03-27 | Snipr Biome Aps | A novel type of crispr/cas system |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1309427B1 (it) * | 1999-05-28 | 2002-01-23 | Mendes S U R L | Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso |
| WO2007070052A2 (en) * | 2005-12-14 | 2007-06-21 | Oxthera, Inc. | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease |
| US9283252B2 (en) * | 2008-09-30 | 2016-03-15 | Meiji Co., Ltd. | Lactic acid bacterium having high oxalic acid decomposition ability |
| US11273184B2 (en) * | 2015-08-31 | 2022-03-15 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
| EP3468572B1 (en) * | 2016-06-13 | 2022-03-02 | OxThera Intellectual Property AB | Compositions and methods for the treatment or prevention of oxalate-related disorders |
| CN111655841A (zh) * | 2017-06-21 | 2020-09-11 | 同生运营公司 | 用于治疗紊乱的细菌 |
| JP2020527025A (ja) * | 2017-07-12 | 2020-09-03 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| IT201800005355A1 (it) * | 2018-05-14 | 2019-11-14 | Lactobacillus amylovorus SGL 14: attività probiotiche e riduzione dell’ossalato enterico |
-
2021
- 2021-01-14 BR BR112022013867A patent/BR112022013867A2/pt not_active IP Right Cessation
- 2021-01-14 CN CN202180020940.5A patent/CN115335066A/zh active Pending
- 2021-01-14 US US17/792,030 patent/US20230092431A1/en not_active Abandoned
- 2021-01-14 JP JP2022542946A patent/JP2023511282A/ja active Pending
- 2021-01-14 EP EP21741375.6A patent/EP4090343A4/en not_active Withdrawn
- 2021-01-14 AU AU2021207879A patent/AU2021207879A1/en not_active Abandoned
- 2021-01-14 CA CA3167754A patent/CA3167754A1/en active Pending
- 2021-01-14 WO PCT/US2021/013401 patent/WO2021146397A1/en not_active Ceased
- 2021-01-14 IL IL294710A patent/IL294710A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511282A5 (https=) | ||
| Plata et al. | The gut microbiota and its relationship with chronic kidney disease | |
| Fei et al. | Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease | |
| US20210154247A1 (en) | Compositions and methods for the treatment of type 1 diabetes | |
| US20200121743A1 (en) | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease | |
| US20230348918A1 (en) | Genetically Modified Bacteria Stably Expressing IL-10 and Insulin | |
| Wang et al. | Modulatory effect of Lactobacillus acidophilus KLDS 1.0738 on intestinal short‐chain fatty acids metabolism and GPR41/43 expression in β‐lactoglobulin–sensitized mice | |
| Yang et al. | Gut bacteria in alcohol-associated liver disease | |
| Wei et al. | Hypoglycemic effects of inactivated Lactobacillus brevis YM 1301 on T2DM Mice | |
| AU2022244381A9 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
| US20230201316A1 (en) | Atp-hydrolyzing enzyme useful for treating dysbiosis | |
| US10383921B2 (en) | Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis | |
| CN106617081A (zh) | 长链菊粉调节急性胰腺炎症及其引起的相关组织损伤的作用 | |
| EP4034144A1 (en) | Treatment of celiac disease | |
| JP2025534764A (ja) | 高フェニルアラニン血症を軽減するためのフェニルアラニンアンモニアリアーゼ、フェニルアラニントランスポーターおよびｌ－アミノ酸デアミナーゼを発現する組み換え細菌 | |
| Glassner et al. | What Is the Role of Probiotics for Patients With IBD? | |
| WO2024129974A1 (en) | Recombinant bacteria for use in the treatment of disorders in which oxalate is detrimental | |
| CN117083068A (zh) | 经工程化以治疗其中草酸盐有害的病症的细菌 | |
| O'hara et al. | Probiotics, prebiotics, and inflammatory bowel disease | |
| WO2023141744A1 (zh) | 一种重组乳酸乳球菌、微胶囊及其应用 | |
| HK40065260A (en) | Compositions and methods for the treatment of type 1 diabetes | |
| Keohane et al. | Therapeutic manipulation of the microbiota in inflammatory bowel disease: antibiotics and probiotics | |
| HK1262225B (en) | Compositions and methods for the treatment of type 1 diabetes |